Evidence map›Paper›PMID 41054261›Full record

ArticleCancer biology & therapy2025

Loss of ACSL1 fuels ferroptosis resistance in clear cell renal carcinoma.

Shangguo Wang, Yuxiong Wang, Bin Liu, Dan Zhang, Zehua Zhang, Hongxia Yang, Guangtao Li, Xiaodong Zhao, Jiaxin Liu, Qianhui Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shangguo WangDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.ORCID 0009-0007-3174-890X
Yuxiong WangDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Bin LiuDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Dan ZhangKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Zehua ZhangDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Hongxia YangKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Guangtao Li
Xiaodong ZhaoDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Jiaxin LiuDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Qianhui LiKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Yifan SongKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Yanghe ZhangDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.
Yishu WangKey Laboratory of Pathobiology, Ministry of Education, Jilin University, Changchun, Jilin, China.
Honglan ZhouDepartment of Urology II, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC), the most common kidney cancer subtype, is marked by lipid metabolism reprogramming and therapy resistance. Ferroptosis-an iron-dependent, lipid peroxidation-driven cell death-has gained attention as a therapeutic strategy. This study investigates the role of ACSL1, a key lipid metabolism enzyme, in ccRCC.

methodsUsing TCGA/GEO datasets, qPCR, immunohistochemistry, and immunofluorescence, ACSL1 expression and clinical significance were analyzed. Functional assays with ACSL1-overexpressing ccRCC cells and a xenograft mouse model evaluated its impact on tumor behavior. Transcriptomics and lipidomics, alongside ROS, ferroptosis, and p53 inhibitors, were applied to uncover mechanisms.

resultsACSL1 is markedly downregulated in ccRCC and predicts poor prognosis. Overexpression suppressed proliferation and migration, induced cell death, and slowed tumor growth. Mechanistically, ACSL1 elevated ROS, activated p53, downregulated SLC7A11/GPX4, and triggered ferroptosis. Blocking ROS or p53 reversed these effects, confirming a ROS-p53-SLC7A11/GPX4 feedback loop.

conclusionACSL1 functions as a tumor suppressor in ccRCC by inducing ferroptosis via the ROS-p53-SLC7A11/GPX4 axis. It holds promise as a prognostic biomarker and therapeutic target in ccRCC.

Indexed as

Carcinoma, Renal CellCoenzyme A LigasesFerroptosisKidney NeoplasmsAmino Acid Transport System y+AnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLong-Chain-Fatty-Acid-CoA LigaseMaleMicePhospholipid Hydroperoxide Glutathione PeroxidasePrognosisACSL1 protein, humanAmino Acid Transport System y+Coenzyme A LigasesLong-Chain-Fatty-Acid-CoA LigasePhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciesSLC7A11 protein, humanTumor Suppressor Protein p53ACSL1ccRCCferroptosisp53ROS

Identifiers

PMID41054261
PMCPMC12505508

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.